Henan Lingrui Pharmaceutical Co., Ltd.

600285

CNE000001501

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2024-09-20			5-day change	1st Jan Change
19.07 ^CNY	-0.57%		+1.60%	+11.46%

09-18	Chinese Stocks Rise On Market Resumption; Lingrui Pharmaceutical Jumps 6%	MT
09-18	Henan Lingrui Pharmaceutical Plans Further 50-Million-Yuan Investment in Xiamen Jinyixing Fund; Shares Up 5%	MT

Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.

July 02, 2021

From April 1, 2021 to June 30, 2021, the company has repurchased 13,300,125 shares, representing 2.35% for CNY 129.45 million. With this, the company has completed the repurchase of 16,199,425 shares, representing 2.86% for CNY 154.67 million under the buyback announced on February 2, 2021.

Latest news about Henan Lingrui Pharmaceutical Co., Ltd.

Chinese Stocks Rise On Market Resumption; Lingrui Pharmaceutical Jumps 6%	09-18	MT
Henan Lingrui Pharmaceutical Plans Further 50-Million-Yuan Investment in Xiamen Jinyixing Fund; Shares Up 5%	09-18	MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-12	CI
Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug	05-13	MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Henan Lingrui Pharma Registers Chewable Asthma Drug in China	04-19	MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-05	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 1, 2022 has expired with 19,086,325 shares, representing 3.39% for CNY 184.47 million.	22-01-30	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	22-01-03	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	21-10-07	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-30	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	21-07-02	CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.	21-04-01	CI
Henan Lingrui Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	21-02-01	CI
Henan Lingrui Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	21-01-31	CI

Chart Henan Lingrui Pharmaceutical Co., Ltd.

Duration

Period

Chart Henan Lingrui Pharmaceutical Co., Ltd.

More charts

Company Profile

Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.

Employees

2,530

Sector

Pharmaceuticals

Calendar

2024-10-24 - Q3 2024 Earnings Release (Projected)

More about the company